精神药物微生物组学:系统综述与荟萃分析
结果显示精神药物与肠道微生物组组成改变相关,基线微生物组组成与疗效和耐受性相关。
要点
- 精神药物(抗精神病药和抗抑郁药)治疗与肠道微生物组α和β多样性改变相关。
- 基线肠道微生物组组成与抗抑郁药疗效和耐受性相关。
- 肠道微生物组可能双向影响精神药物的疗效与耐受性。
核心结论
- 精神药物治疗与肠道微生物组组成改变相关,且肠道微生物组可能影响这些药物的疗效与耐受性。
主要发现
- 抗精神病药和抗抑郁药治疗分别与α多样性(4项研究;SMD=0.12;95%CI 0.01-0.23;p=.04;I²=14%)和β多样性(F=15.59;R²=0.05;p<.001)显著变化相关。
- 基线肠道微生物组组成改变与耐受性和疗效结局相关,包括抗抑郁药应答(2项研究;α多样性;SMD=2.45;95%CI 0.50-4.40;p<.001;I²=0%)。
临床怎么用
- 精神科临床可关注肠道微生物组作为精神药物疗效与耐受性的潜在生物标志物。
- 未来可探索基于肠道微生物组的分层治疗策略以改善精神药物治疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the interactions between the gut microbiome and psychotropic medications (psycho-pharmacomicrobiomics) could improve treatment stratification strategies in psychiatry. In this systematic review and meta-analysis, we first explored whether psychotropics modify the gut microbiome; second, we investigated whether the gut microbiome affects the efficacy and tolerability of psychotropics. METHODS: Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched (November 2022) for longitudinal and cross-sectional studies that investigated the effect of psychotropics on the gut microbiome. The primary outcome was the difference in diversity metrics (alpha and beta) before and after treatment with psychotropics (longitudinal studies) and in medicated compared with unmedicated individuals (cross-sectional studies). Secondary outcomes included the association between gut microbiome and efficacy and tolerability outcomes. Random effect meta-analyses were conducted on alpha diversity metrics, while beta diversity metrics were pooled using distance data extracted from graphs. Summary statistics included standardized mean difference and Higgins I2 for alpha diversity metrics and F and R values for beta diversity metrics. RESULTS: Nineteen studies were included in our synthesis; 12 investigated antipsychotics and 7 investigated antidepressants. Results showed significant changes in alpha (4 studies; standard mean difference: 0.12; 95% CI: 0.01-0.23; p = .04; I2: 14%) and beta (F = 15.59; R2 = 0.05; p < .001) diversity metrics following treatment with antipsychotics and antidepressants, respectively. Altered gut microbiome composition at baseline was associated with tolerability and efficacy outcomes across studies, including response to antidepressants (2 studies; alpha diversity; standard mean difference: 2.45; 95% CI: 0.50-4.40; p < .001, I2: 0%). CONCLUSIONS: Treatment with psychotropic medications is associated with altered gut microbiome composition, and the gut microbiome may in turn influence the efficacy and tolerability of these medications.
引用
- Minichino A, Preston T, Fanshawe JB, et al. Psycho-Pharmacomicrobiomics: A Systematic Review and Meta-Analysis. Biol Psychiatry. 2023. PMID: 37567335. doi:10.1016/j.biopsych.2023.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。